DEXCOM INC — fact timeline

DEXCOM INC shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-05-27 meeting.

“Dexcom stockholders approved, on a non-binding advisory basis, the compensation of Dexcom’s named executive officers”

DEXCOM INC shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-27 meeting.

“Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom’s independent registered public accounting firm”

DEXCOM INC shareholders approved Election of Directors at the 2026-05-27 meeting.

“Dexcom stockholders elected the following twelve nominees to the Company’s board of directors”

DEXCOM INC reported fiscal year 2026 results: revenue $5.16 - $5.25 billion. Guidance raised.

“Dexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following levels: • Revenue of $5.16 - $5.25 billion (approximately 11-13% growth) • Non-GAAP Gross Profit Margin of approximately 63-64% • Non-GAAP Operating Margin of approximately 23-23.5% • Adjusted EBITDA Margin of approximately 31-31.5%”

DEXCOM INC reported quarter ended March 31, 2026 results: revenue $1.192 billion, net income $199.5 million, EPS $0.51.

“(Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: • Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic 1 basis. • U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic 1 basis,”

Jacob S. Leach changed role as President and Chief Operating Officer at DEXCOM INC.

“On May 9, 2025, Jacob S. Leach was promoted to President and Chief Operating Officer of DexCom, Inc. (the “Company”) effective immediately.”

Karen Dahut resigned as Director at DEXCOM INC.

“On May 1, 2025, Karen Dahut, a director of DexCom, Inc. (the “Company”), resigned from the Board of Directors (the “Board”) of the Company and all committees thereof effective May 8, 2025.”

DEXCOM INC engaged Deloitte & Touche LLP as its auditor.

“(b) Engagement of New Independent Registered Public Accounting Firm On March 21, 2025, the Audit Committee approved the engagement of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”

DEXCOM INC dismissed Ernst & Young LLP as its auditor.

“(a) Dismissal of Independent Registered Public Accounting Firm On March 21, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of DexCom, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.”

Renée Galá was appointed as director at DEXCOM INC.

“On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately.”

DEXCOM INC reported the quarter ended March 31, 2024 results: revenue $921.0 million, net income $146.4 million, or $0.36 per diluted share, EPS $0.36 per diluted share. Guidance reaffirmed.

“(Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: • Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic 1 basis. • U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on”

DEXCOM INC terminated BofA Warrant Transactions with Bank of America, N.A. (effective 2024-02-13).

“Pursuant to the terms of the Termination Agreement, the BofA Warrant Transactions with respect to an aggregate of 10.3 million shares of Common Stock will be terminated.”

DEXCOM INC entered into Termination Agreement with Bank of America, N.A. (effective 2024-02-13).

“On February 13, 2024, DexCom, Inc. (the “Company”) entered into a warrant termination agreement (the “Termination Agreement”) with Bank of America, N.A., (“BofA”), to terminate outstanding warrants to purchase shares of the Company’s common stock”

DEXCOM INC updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).

“On February 8, 2024, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.”

DEXCOM INC reported fiscal year 2024 results: revenue $4.15 billion to $4.35 billion. Guidance initiated.

“For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion”

DEXCOM INC reported fiscal year 2023 results: revenue $3.62 billion.

“For fiscal year 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion”

DEXCOM INC reported the fourth quarter ended December 31, 2023 results: revenue $1.030 billion.

“preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 is expected to be at least $1.030 billion”

DEXCOM INC reported the quarter ended September 30, 2023 results: revenue $975.0 million, net income $120.7 million, or $0.29 per diluted share, EPS $0.29 per diluted share. Guidance raised.

“financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: • Revenue grew 27% versus the same quarter of the prior year to $975.0 million on a reported basis and 26% on an organic 1 basis. • U.S. revenue growth of 24% and international revenue growth of 33% on a reported basis. International revenue growth was 30%”

Rimma Driscoll was elected as Director at DEXCOM INC.

“Effective on August 24, 2023, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) elected Rimma Driscoll to fill a vacancy on the Board and to replace Nicholas Augustinos as a member of the Audit Committee of the Board and the Technology Committee of the Board.”

DEXCOM INC reported the quarter ended June 30, 2023 results: revenue $871.3 million, net income $115.9 million, EPS $0.28 per diluted share. Guidance raised.

“its financial results as of and for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights: • Revenue grew 25% versus the same quarter of the prior year to $871.3 million on a reported basis and 26% on an organic 1 basis. • U.S. revenue growth of 21% and international revenue growth of 38% on a reported basis. International revenue growth was 40%”

DEXCOM INC shareholders rejected Stockholder proposal regarding pay equity disclosure at the 2023-05-18 meeting.

“Holders of Dexcom’s common stock rejected the stockholder proposal regarding pay equity disclosure: Number of Shares Shares Voted in Favor: 116,858,384 Shares Voted Against: 208,464,621 Shares Abstaining: 11,534,433 Broker Non-Votes: 16,349,688”

DEXCOM INC shareholders approved Non-binding advisory vote on the frequency of say-on-pay votes at the 2023-05-18 meeting.

“Holders of Dexcom’s common stock voted to approve the non-binding advisory resolution on the frequency of the advisory vote on executive compensation: Number of Shares Shares Voted for One Year: 333,293,629 Shares Voted for Two Years: 79,793 Shares Voted for Three Years: 3,311,723 Shares Abstaining: 172,294”

DEXCOM INC shareholders approved Advisory vote on executive compensation at the 2023-05-18 meeting.

“Holders of Dexcom’s common stock voted to approve the non-binding vote on an advisory resolution on compensation paid to Dexcom’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including compensation discussion and analysis, compensation tables and narrative discussion: Number of Shares Shares Voted in Favor: 314,149,421 Shares Voted Against: 22,473,694 Shares Abstaining: 234,324 Broker Non-Votes: 16,349,688”

DEXCOM INC shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2023-05-18 meeting.

“Holders of Dexcom’s common stock voted to ratify the selection by the Audit Committee of the Board of Directors for the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2023: Number of Shares Shares Voted in Favor: 337,756,034 Shares Voted Against: 15,338,845 Shares Abstaining: 112,248”

DEXCOM INC shareholders approved Election of seven directors at the 2023-05-18 meeting.

“Holders of Dexcom’s common stock voted to elect seven directors, each to serve until Dexcom’s 2024 Annual Meeting of Stockholders and until their successor has been elected and qualified, or until their earlier death, resignation or removal as follows: Name For Against Abstentions Broker Non-Votes Steven R. Altman 325,874,437 10,807,788 175,214 16,349,688 Richard A. Collins 328,449,788 8,223,746 183,905 16,349,688 Karen Dahut 333,283,921 3,395,511 178,007 16,349,688 Mark G. Foletta 327,154,744 8,407,194 1,295,501 16,349,688 Barbara E. Kahn 324,355,913 12,324,870 176,656 16,349,688 Kyle Malady 329,175,433 7,502,036 179,970 16,349,688 Eric J. Topol, M.D. 333,532,810 3,150,136 174,493 16,349,688”

DEXCOM INC entered into a notes offering with Initial Purchasers valued at $1.25 billion (effective 2023-05-05).

“On May 5, 2023, DexCom, Inc. (the “ Company ”) completed its previously announced sale of $1.25 billion in aggregate principal amount of its 0.375% Convertible Senior Notes due 2028 (the “ Notes ”), which includes the full exercise of the Initial Purchasers’ option to purchase up to an additional $150.0 million in aggregate principal amount of Notes, to the Initial Purchasers (as defined below) in a private placement”

DEXCOM INC reported fiscal year 2023 results: revenue approximately $3.400 - 3.515 billion. Guidance raised.

“The company is updating fiscal year 2023 revenue guidance, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels: • Revenue of approximately $3.400 - 3.515 billion (17-21% growth)”

DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.

“First Quarter 2023 Financial Results Revenue: In the first quarter of 2023, worldwide revenue grew 18% to $741.5 million on a reported basis, up from $628.8 million in the first quarter of 2022.”

DEXCOM INC reported quarter ended March 31, 2023 results: revenue $741.5 million, net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.

“its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: • Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic 1 basis. • U.S. revenue growth of 17% and international revenue growth of 21% on a reported basis. International revenue growth was 27%”

DEXCOM INC updated its quarter and year ended December 31, 2022 guidance (reaffirmed).

“issued a press release announcing its financial results for the quarter and year ended December 31, 2022”

DEXCOM INC reported fiscal year 2023 results: revenue approximately $3.35 billion to $3.49 billion. Guidance initiated.

“initial financial outlook for fiscal year 2023, including an anticipated range for total revenue of approximately $3.35 billion to $3.49 billion”

DEXCOM INC reported fiscal year 2022 results: revenue approximately $2.91 billion.

“total preliminary, unaudited revenue is expected to be approximately $2.91 billion”

DEXCOM INC reported the fourth quarter ended December 31, 2022 results: revenue at least $815 million.

“preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 is expected to be at least $815 million”

Jacob S. Leach changed role as Executive Vice President, Chief Operating Officer at DEXCOM INC.

“On August 25, 2022, the Board of Directors (the “Board”) of DexCom, Inc. (the “Company”) promoted Jacob S. Leach to Executive Vice President, Chief Operating Officer, effective August 25, 2022.”

Chad M. Patterson resigned as Executive Vice President, Global Marketing at DEXCOM INC.

“On July 5, 2022, DexCom, Inc. (“ Dexcom ”) received notice from Chad M. Patterson of his intention to resign as Executive Vice President, Global Marketing of Dexcom effective on July 15, 2022, in order to pursue another employment opportunity.”

Quentin Blackford resigned as Chief Operating Officer at DEXCOM INC.

“On September 8, 2021, DexCom, Inc. (“ Dexcom ”) received notice from Quentin Blackford of his intention to resign as Chief Operating Officer of Dexcom effective on September 17, 2021, in order to pursue another employment opportunity.”